Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance® registry
Open accessAbstract
Summary: Invasive Fusarium infections occur in immunosuppressed patients, especially those with haematological malignancies. We conducted a descriptive analysis of data from patients with invasive fusariosis identified in the Prospective Antifungal Therapy Alliance registry, which collected data on invasive fungal infections in the United States and Canada from 2004 to 2008. In this series of 65 patients with proven (83.1%) and probable (16.9%) invasive fusariosis, the most common underlying condition was haematological malignancy, in which neutropenia and corticosteroid usage frequently occurred. Seven patients with invasive Fusarium infections had cross‐reactive galactomannan assay results. The survival rate for all patients at 90 days was 44%, which was an improvement compared with historical data. Disseminated disease occurred frequently (35.4%), and patients with and without disseminated disease had survival rates of 33% and 50%, respectively. Posaconazole and voriconazole were the most frequently employed therapies and may be linked to the improved survival rate observed in this patient series. In summary, patients with invasive Fusarium infections continue to have high fatality rates, especially those with disseminated disease. Fusarium infections should be strongly considered in the absence of Aspergillus isolation in patients at high risk of mould infections with positive galactomannan assay test results.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Among 65 cases of invasive fusariosis in the US and Canada, 78.5% were white, 9.2% Asian, 6.2% black, and 4.6% Hispanic ethnicity.
“Among 65 cases of invasive fusariosis in the US and Canada, 78.5% were white, 9.2% Asian, 6.2% black, and 4.6% Hispanic ethnicity [107].”
From Race and ethnicity: Risk factors for fungal infections? (2023) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917 · see citing works
Self-citationFusarium Infections in Immunocompromised Patients
Nucci, M., & Anaissie, E. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-07 · Cited by 979 · see citing works
Dignani, M. C., & Anaissie, E. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00845.x · Cited by 351 · see citing works
Fusarium Infection in Hematopoietic Stem Cell Transplant Recipients
Nucci, M., Marr, K. A., Queiroz‐Telles, F., Martins, C. A. S., Trabasso, P., Costa, S. F., Voltarelli, J. C., Colombo, A. L., Imhof, A., Pasqüini, R., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/383319 · Cited by 332 · see citing works
Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection
Nucci, M., Anaissie, E. J., Queiroz‐Telles, F., Martins, C. A. S., Trabasso, P., Solza, C., Mangini, C., Simões, B. P., Colombo, A. L., Vaz, J., et al. (2003) · Cancer · doi:10.1002/cncr.11510 · Cited by 313 · see citing works
RAAD, I. I., Hachem, R. Y., Herbrecht, R., Graybill, J. R., Hare, R. S., Corcoran, G., & Kontoyiannis, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/503425 · Cited by 299 · see citing works
Azie, N., Neofytos, D., Pfaller, M., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.06.012 · Cited by 222 · see citing works
Self-citationImprovement in the outcome of invasive fusariosis in the last decade
Nucci, M., Marr, K. A., Vehreschild, M. J. G. T., Souza, C. A. D., Velasco, E., Cappellano, P., Carlesse, F. A. D. M. C., Queiroz‐Telles, F., Sheppard, D. C., Kindo, A. J., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12409 · Cited by 197 · see citing works
Cross-Reactivity of Fusarium spp. in the Aspergillus Galactomannan Enzyme-Linked Immunosorbent Assay
Tortorano, A. M., Esposto, M. C., Prigitano, A., Grancini, A., Ossi, C. M., Cavanna, C., & Cascio, G. L. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05946-11 · Cited by 185 · see citing works
Muhammed, M., Anagnostou, T., Desalermos, A. P., Kourkoumpetis, T. K., Carneiro, H. A., Glavis‐Bloom, J., Coleman, J. J., & Mylonakis, E. E. (2013) · Medicine · doi:10.1097/md.0000000000000008 · Cited by 183 · see citing works
International Retrospective Analysis of 73 Cases of Invasive Fusariosis Treated with Voriconazole
Lortholary, O., Obenga, G., Biswas, P., Caillot, D., Chachaty, É., Bienvenu, A., Cornet, M., Greene, J. N., Herbrecht, R., Lacroix, C., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00286-10 · Cited by 181 · see citing works
Earlier Diagnosis of Invasive Fusariosis with Aspergillus Serum Galactomannan Testing
Nucci, M., Carlesse, F. A. D. M. C., Cappellano, P., Varon, A. G., Seber, A., Garnica, M. M., Nouér, S. A., & Colombo, A. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087784 · Cited by 99 · see citing works
The challenge of managing fusariosis
Muhammed, M., Carneiro, H. A., Coleman, J. J., et al. (2011) · Virulence · doi:10.4161/viru.2.2.15015 · Cited by 93 · see citing works
Horn, D. L., Fishman, J. A., Steinbach, W. J., Anaissie, E. J., Marr, K. A., Olyaei, A. J., Pfaller, M. A., Weiss, M. A., Webster, K. M., & Neofytos, D. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.06.008 · Cited by 89 · see citing works
Self-citationTreating disseminated fusariosis: amphotericin B, voriconazole or both?
Ho, D. Y., Lee, J. D., Rosso, F., et al. (2007) · Mycoses · doi:10.1111/j.1439-0507.2006.01346.x · Cited by 84 · see citing works
Fusarium Infection in Lung Transplant Patients
Carneiro, H. A., Coleman, J. J., Restrepo, A., & Mylonakis, E. E. (2010) · Medicine · doi:10.1097/md.0b013e318207612d · Cited by 73 · see citing works
Bourgeois, G. P., Cafardi, J. A., Sellheyer, K., et al. (2010) · PubMed · Cited by 50 · see citing works
Liu, J.-Y., Chen, W.-T., Ko, B., et al. (2011) · Medical Mycology · doi:10.3109/13693786.2011.567304 · Cited by 37 · see citing works
Infections Caused byFusariumSpecies
Torres, H. A., RAAD, I. I., & Kontoyiannis, D. P. (2003) · Journal of Chemotherapy · doi:10.1179/joc.2003.15.supplement-2.28 · Cited by 33 · see citing works
Hu, S., Fan, V. C., Koonapareddy, C., et al. (2007) · Eye & Contact Lens Science & Clinical Practice · doi:10.1097/icl.0b013e3180645d17 · Cited by 24 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Muhammed M, Anagnostou T, Desalermos A et al. Fusarium infec- tion: report of 26 cases and review of 97 cases from the literature. Medicine (Baltimore) 2013; 92: 305-16.
Cited by
Sorted by citations
Race and ethnicity: Risk factors for fungal infections?
Jenks, J. D., Aneke, C. I., Al-Obaidi, M. M., Egger, M., Garcia, L., Gaines, T., Hoenigl, M., & Thompson, G. R. (2023) · PLOS Pathogens · doi:10.1371/journal.ppat.1011025 · Cited by 55 · see citing works
- Authors
- Horn, D. L., Freifeld, A. G., Schuster, M. G., Azie, N. E., Franks, B., & Kauffman, C. A.
- Affiliations
- David Horn LLC Doylestown PA USA
- University of Nebraska Medical Center (US)
- University of Pennsylvania (US)
- Astellas Pharma (United States) (US)
- University of Michigan (US)
- Corresponding author
- Horn, David L.
- Venue
- Mycoses
- Publisher
- Wiley
- Published
- 2014-06-18
- Volume
- 57
- Issue
- 11
- Pages
- 652-658
- ISSN
- 0027-5557 (ISSN-L)
- 0933-7407
- 1439-0507
- OpenAlex
- W1967749841
- Cited by
- 83
- References
- 20
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 5 · 2023: 7 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 7 · 2017: 10 · 2016: 13 · 2015: 8 · 2014: 1
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Mycoses (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- Massachusetts General Hospital
- University of Nebraska Medical Center
- Emory University
- University of Minnesota
- School of Medicine, Oregon Health and Science University
- University of Washington
- Johns Hopkins University
- Thomas Jefferson University
- University of Arkansas for Medical Sciences
- City of Hope
- Astellas Pharma
- University of Texas MD Anderson Cancer Center
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- invasive fusariosis, Fusarium, hematologic malignancies, immunosuppression, neutropenia, corticosteroid use, disseminated disease, survival, posaconazole, voriconazole, galactomannan assay, antifungal therapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antifungal Agents, Canada, Female, Fusarium, Humans, Male, Middle Aged, Prospective Studies, Registries, Triazoles, United States, Survival Analysis, Treatment Outcome, Young Adult, Fusariosis, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
